問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Urology

Division of Others-

Division of Obstetrics & Gynecology

National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

蘇五洲Su, Wu-Chou
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years

Recruiting Trial

175Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇五洲

List

382Cases

2015-01-01 - 2024-11-26

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2018-08-01 - 2026-12-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2023-04-01 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2011-10-01 - 2013-09-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2017-06-08 - 2019-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2019-04-01 - 2022-12-31

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting1Sites

Terminated7Sites

2016-01-01 - 2019-08-31

Phase III

An international, randomised, multi-centre, active controlled, open-label Phase III study evaluating the efficacy of in patients with T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on one epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    AZD9291

Participate Sites
9Sites

Terminated8Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

鍾飲文
Kaohsiung Municipal Gangshan Hospital

未分科

2011-03-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2007-11-01 - 2011-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-02-26 - 2018-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 21 22 23 24 25 39
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB